Methodological approaches to preclinical evaluation of immunobiological serum products and their side effects

Analysis of methodological approaches to preclinical evaluation of sensitizing activity of horse serum products shows that the anaphylactogenicity scale recommended in national regulatory documents is imperfect as it is not capable of fully predicting the safety of the clinical use of products. The article demonstrates feasibility of another methodological approach to preclinical evaluation of sensitizing activity of heterologous serum products which is based on calculation of a sensitizing dose inducing anaphylactic reactions in 50 % of guinea pigs. This approach will make it possible to more effectively predict side effects of already authorized heterologous immunoglobulins and drugs currently under development, and to select a clinical use strategy on a case-by-case basis.

сенсибилизирующая активность, сывороточные иммунобиологические лекарственные препараты, иммуноглобулины из сыворотки крови лошадей, анафилактогенность, методический подход, sensitizing activity, immunobiological serum products, horse serum immunoglobulins, anaphylactogenicity, methodological approach

1. Medunitsyn NV, Mironov AN, Movsesyants AA. Theory and practice of vaccinology. Moscow: Remedium; 2015 (in Russian).

2. Penyevskaya NA, Rudakov NV. The effectiveness of immunoglobulin preparations for post-exposure prophylaxis of tick-borne encephalitis in Russia (Review a half-century of experience). Medical Parasitology and Parasitic Diseases 2010; (1): 53–9 (in Russian).

3. Borisevich IV, Potryvayeva NV, Melnikov SA, Yevseyev AA, Krasnyansky VP, Maksimov VA. Design of equine serum-based Marburg virus immunoglobulin. Voprosy virusologii 2008; 53(1): 39–41 (in Russian).

4. Krasnyansky VP, Mikhaylov VV, Borisevich IV, Potryvaeva NV, Melnikov SA, Timankova GD. Liquid preparation containing immunoglobulin efficient against Marburg fever from horse blood serum (horse immunoglobulin Marburg). Patent RUS. 2257916 04. 12.2003 (in Russian).

5. Pyankov OV, Setoh YX, Bodnev SA, Edmonds JH, Pyankova OG, Pyankov SA, et al. Successful post-exposure prophylaxis of Ebola infected non-human primates using Ebola glycoprotein-specific equine Ig G. Scientific reports 2017. Available from: http://www.nature.com/articles/srep41537.

6. Zheng X, Wong G, Zhao Y, Wang H, He Sh, Bi Y, et al. Treatment with hyperimmune equine immunoglobulin or immunoglobulin fragments completely protects rodents from Ebola virus infection. Scientific reports 2016. Available from: http://www.nature.com/articles/srep24179.

7. Synyak KM, Zharko TR, Werner OM. Guidebook on medical immunobiological drugs. Kiev: 1992 (in Russian).

8. Khmelev AL, Borisevich IV, Chernikova NK, Makhlay AA, Mikhaylov VV, Yakovlev AK, et al. Evaluation of safety of prophylactic use of immunoglobulins against viral hemorrhagic fevers from horse blood sera. Journal of microbiology, epidemiology and immunobiology 2012; (6): 103–6 (in Russian).

9. Borisevich IV, Chernikova NK, Markov VI, Krasnyanskiy VP, Borisevich SV, Rozhdestvenskiy EV. An experience in the clinical use of specific immunoglobulin from horse blood serum for prophylaxis of Ebola haemorrhagic fever. Voprosy virusologii 2017; 62(1): 25–9 (in Russian).

10. Mironov AN, ed. Guidelines for preclinical studies of medicines (immunobiological medicines). Part 2. Moscow: Grif i K; 2012. P. 235–6 (in Russian).

11. Krasnyansky VP, Gradoboev VN, Borisevich IV, Potryvaeva NV, Lebedinskaya EV, Chernikova NK, Timankova GD. Development and study of the properties of immunoglobulin against Lassa fever. Voprosy virusologii 1997; 42(4): 168–71 (in Russian).

12. Krasnyansky VP, Mikhaylov VV, Lukin EP, Borisevich IV, Potryvaeva NV, Melnikov SA, et al. The preparation containing immunoglobulin against VEE from horse blood serum liquid (immunoglobulin against VEE from horse blood serum). Patent RUS 2261113 04.12.2003 (in Russian).

13. Mikhaylov VV, Borisevich IV, Timankova GD, Krasnyansky VP, Potryvaeva NV, Lebedinskaya EV, Chernikova NK. The preparation containing immunoglobulin against Ebola fever from horse blood serum liquid (immunoglobulin Ebola). Patent RUS 2130318 05.07.1996 (in Russian).

14. Khmelev AL, Pantyukhov VB, Syromyatnikova SI, Potryvaeva NV, Melnikov SA, Pirozhkov AP, et al. The preparation containing immunoglobulin against Bolivian hemorrhagic fever from horse blood serum, intramuscular solution. Patent of the Russian Federation ¹ 2342952; 2007 (in Russian).

15. Medical immunobiological preparations. V. 2. Human immunoglobulins, sera, heterologous immunoglobulins, monoclonal antibodies, probiotics, bacteriophages, allergens, cytokines (administered to humans). Moscow: Gella-Print; 2011 (in Russian).

16. Zubavichene NM, Dedkova LM, Sergeev NN, Ofitserov VI. Sensitizing and virus-neutralizing characteristics of goat immunoglobulins to Ebola virus. Voprosy virusologii 2002; 47(2): 45–8 (in Russian).

17. Ashmarin IP, Vorobyev AA. Statistical methods in microbiological studies. Leningrad; 1962 (in Russian).